dMed Biopharmaceutical Co.
Latest round
- Series C
Last raised
- Jul 2021
Total raised
- $214M
Investors
- 13
About dMed Biopharmaceutical Co.
, Ltd. operates as a clinical contract research organization that provides drug services and solutions to improve and accelerate clinical and drug development. It has branch offices in New York and Eschborn. The chairman of the board, Lingshi Tan, graduated from University of Pittsburgh and is a chairman of the Drug Information Association Board of Directors. The company has cooperated with ClinsChain, Eurofins, KingMed Diagnostics and other enteprises. In October, it changed its name from dMed to Caidya. The company mainly provides new drug R&D contract outsourcing services, providing users with clinical trial design, data management and system development, clinical development and registration strategy services. The company's services can be used in oncology, hematology, rare diseases, pediatric diseases and other disciplines. The company generates revenue by providing new drug R&D contract outsourcing services including early clinical development, clinical trial operations, data management, and drug safety.
Who invested in dMed Biopharmaceutical Co.
13 investors across 5 rounds
See all investors in dMed Biopharmaceutical Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about dMed Biopharmaceutical Co.
Who invested in dMed Biopharmaceutical Co.?
dMed Biopharmaceutical Co. has 13 investors on record across 5 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has dMed Biopharmaceutical Co. raised?
dMed Biopharmaceutical Co. has raised 5 venture rounds. Sign up free to see how much each round raised and the total.
When did dMed Biopharmaceutical Co. last raise money?
dMed Biopharmaceutical Co.'s most recent round on record is a Series C, in Jul 2021.
What does dMed Biopharmaceutical Co. do?
dMed Biopharmaceutical Co. is a pharmaceuticals company.
Where is dMed Biopharmaceutical Co. headquartered?
dMed Biopharmaceutical Co. is headquartered in Shanghai, China.
Which VCs invest in companies like dMed Biopharmaceutical Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back pharmaceuticals companies at dMed Biopharmaceutical Co.'s stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series C
Raising like dMed Biopharmaceutical Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.